title: Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines.
abstract: Receptor for Advanced Glycation End Products (RAGE) is an oncogenic trans-membranous receptor overexpressed in various human cancers. However, the role of RAGE in breast cancer development and proliferation is still unclear. In this study, we demonstrated that RAGE expression levels are correlated to the degree of severity of breast cancer. Furthermore, there is a decrease in the proliferation of all sub-types of breast cancer, MCF-7, SK-Br-3 and MDA-MB-231, as a result of the effect of RAGE siRNA. RAGE siRNA arrested cells in the G1 phase and inhibited DNA synthesis (p < 0.05). Moreover, qRT-PCR and Western Blot results demonstrated that RAGE siRNA decreases the expression of transcriptional factor NF-κB p65 as well as the expression of cell proliferation markers PCNA and cyclinD1. RAGE and RAGE ligands can thus be considered as possible targets for breast cancer management and therapy.
authors.affiliation: Cell Transplantation and Gene Therapy Institute, Department of Radiology, the Third Xiang Ya Hospital of Central South University, Changsha 410013, China. wawe01cn@yahoo.com.cn.
authors.forename: Al-Madhagi
authors.initials: AM
authors.lastname: Radia
authors.forename: Al-Madhagi
authors.initials: AM
authors.lastname: Yaser
authors.forename: Xiaoqian
authors.initials: X
authors.lastname: Ma
authors.forename: Juan
authors.initials: J
authors.lastname: Zhang
authors.forename: Cejun
authors.initials: C
authors.lastname: Yang
authors.forename: Qiong
authors.initials: Q
authors.lastname: Dong
authors.forename: Pengfei
authors.initials: P
authors.lastname: Rong
authors.forename: Bin
authors.initials: B
authors.lastname: Ye
authors.forename: Sheng
authors.initials: S
authors.lastname: Liu
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
mesh_terms: D017209:Apoptosis; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival; D019938:Cyclin D1 / Q000235:genetics; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005260:Female; D059585:G1 Phase Cell Cycle Checkpoints; D015870:Gene Expression; D055785:Gene Knockdown Techniques; D006801:Humans; D061986:MCF-7 Cells; D018809:Proliferating Cell Nuclear Antigen / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics* / Q000627:therapeutic use; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000378:metabolism; D051996:Transcription Factor RelA / Q000235:genetics; D064726:Triple Negative Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology
chemical_list: C530104:CCND1 protein, human; D004273:DNA, Neoplasm; D018809:Proliferating Cell Nuclear Antigen; C498143:RELA protein, human; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D034741:RNA, Small Interfering; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; D051996:Transcription Factor RelA; D019938:Cyclin D1